A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

Inclusion Criteria:

• Primary psychiatric diagnosis of recurrent major depressive disorder, withoutpsychotic features, based on clinical assessment using diagnostic and statisticalmanual of mental disorders (DSM)-5 criteria and confirmed with the miniinternational neuropsychiatric interview (MINI)

• Participant had to have at least one previous major depressive disorder (MDD)episode prior to their current episode

• Were first diagnosed with depression before the age of 55

• Are in a current episode of depression: Episode length must be at least 2 months butnot longer than 24 months

• Have taken 0, 1, or 2 treatments for depression in your current episode

• Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2)at screening

Exclusion Criteria:

• Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT),transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), orketamine/esketamine within the current or past major depressive episodes

• Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderlinepersonality disorder, antisocial personality disorder, or currentobsessive-compulsive disorder

• Post-traumatic stress disorder within the past three years of screening

• Dementia, any dementing disease, intellectual disability, or neurocognitive disorder

• History of Alcohol and Substance use disorders within 6 months of screening, withthe exclusion of nicotine, caffeine, and mild cannabis use disorder, according tothe MINI and Clinical Assessment

• Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients